Pharmos to Offer Shares of Its Common Stock to Public
Iselin, NJ,
December 2, 2003 - Pharmos Corporation (Nasdaq:
PARS) announced today that it expects to offer shares
of its common stock to the public, subject to market and
other conditions. The offering is being made from a shelf
registration statement filed by Pharmos on November 18,
2003, as amended, that was declared effective by the Securities
and Exchange Commission on December 2, 2003. C.E. Unterberg,
Towbin and Harris Nesbitt Gerard will act as underwriters
for the offering.
This press release does not constitute an
offer to sell or the solicitation of an offer to buy these
securities, nor shall there be any sale of these securities
in any state or foreign jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such
state or foreign jurisdiction. The offering of common
stock may be made only be means of a prospectus, a copy
of which will be available from C.E. Unterberg, Towbin,
350 Madison Avenue, New York, New York 10017 or Harris
Nesbitt Gerard, 360 Madison Avenue, New York, New York
10017.
Pharmos Corporation is a bio-pharmaceutical
company that discovers and develops new drugs to treat
a range of neuro-inflammatory disorders. Pharmos has a
portfolio of drug candidates under development, as well
as discovery, preclinical and clinical capabilities. Pharmos’
executive offices and clinical and regulatory group are
located in Iselin, New Jersey, and it conducts research
and development through its wholly-owned subsidiary, Pharmos
Ltd., in Rehovot, Israel.
Contacts:
Gale T. Smith – U.S.
732.452.9556
Gale.Smith@pharmos-us.com
Irit Kopelov – Israel
08-940-9679
iritk@pharmos.com
back
to News Room
